The Effects of Interrupting Prolonged Sitting With Bouts of Physical Activity on Neurocognitive Function in Obesity (SITLess)
SIT Less! Interrupting Prolonged Sitting With Brief Physical Activity Bouts to Improve Neurocognitive Function in Adults With Obesity
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Dominika M Pindus, PhD
- Phone Number: 1217300-7317
- Email: pindus@illinois.edu
Study Locations
-
-
Illinois
-
Urbana, Illinois, United States, 61801
- University of Illinois at Urbana-Champaign
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
• Informed consent
- Age 21-64 years
- BMI within ≥ 30 and < 40 kg/m2 range
- Pre-menopausal
- Fasting plasma glucose (FPG) < 100 mg/dL
- Resting blood pressure: systolic < 160 mmHg or diastolic < 100 mmHg
- Employed in sedentary occupation (i.e., participants reporting sitting on average 6 h/d on a weekday and with objectively assessed sitting time ≥ 8 h/day)
- Physically inactive (i.e., engaging in < 150 min of moderate or < 75 min of vigorous or any combination of the two intensities per week)
- Participants must have had no prior diagnosis of cognitive or physical disability (e.g., ADHD, severe asthma, epilepsy, chronic kidney disease, or dependence upon a wheelchair/walking aid)
- Free of medication that could affect cognitive function or metabolism
- Normal or corrected-to-normal vision based on the minimal 20/20 standard in order to complete the cognitive task (below 20/20 vision)
- Must be able to engage in vigorous exercise
- Fluency in English
Exclusion Criteria:
• Impaired glucose tolerance defined as fasting plasma glucose (FPG) < 100 mg/dL
- Oral glucose tolerance test (OGTT) blood glucose values ≥ 200 mg/dL
- Participants with any psychiatric, neurological or metabolic disorder
- Participants who have or are currently taking the medication that could affect cognitive function, metabolism or weight status
- Participants with substance abuse
- Participants with a standardized score on the test of general cognitive abilities below 85
- Participants with anemia
- Pregnant women or those with a possible pregnancy
- History of injury to the spinal cord
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Physical Activity Breaks Intervention
Participants will sit continuously for 3 hours and interrupt their sitting by walking on a treadmill at a moderate intensity for 3 min.
|
Participants will be asked to walk on a treadmill for 3 min at a moderate intensity (55% of heart rate reserve) at an increasing speed and incline to reach and maintain their target heart rate.
|
|
Active Comparator: Talking Breaks Control
Participants will sit continuously for 3 hours.
They will interrupt solitary sitting activities (while remaining seated) by talking to a researcher for 3 min on pre-selected topics of general interest.
|
Every 30 min a researcher will start a brief conversation with a participant based on a pre-selected topic, which will change with each break.
Topics are standardized across participants and include, for example, pollution, smart clothes, and hydration.
A presentation will be followed by questions and answers.
The break will last 3 min.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neuroelectric measures of inhibitory control - P3 component of event-related potentials (ERPs)
Time Frame: Assessed immediately before and after the intervention (on the same day as intervention)
|
The change in the P3 component measured during the modified flanker task
|
Assessed immediately before and after the intervention (on the same day as intervention)
|
|
Neuroelectric measures of inhibitory control - N2 component of event-related potentials (ERPs)
Time Frame: Assessed immediately before and after the intervention (on the same day as intervention)
|
The change in the N2-ERP component measured during the modified flanker task.
|
Assessed immediately before and after the intervention (on the same day as intervention)
|
|
Inhibitory control measured with a modified flanker task - accuracy
Time Frame: Assessed immediately before and after the intervention (on the same day as intervention)
|
The change in accuracy on the modified flanker task
|
Assessed immediately before and after the intervention (on the same day as intervention)
|
|
Inhibitory control measured with a modified flanker task - reaction time
Time Frame: Assessed immediately before and after the intervention (on the same day as intervention)
|
The change in measures of reaction time on the modified flanker task
|
Assessed immediately before and after the intervention (on the same day as intervention)
|
|
Neuroelectric measures of working memory - P3-ERP component
Time Frame: Assessed immediately before and after the intervention (on the same day as intervention)
|
The change in the P3-ERP component during the n-back task.
|
Assessed immediately before and after the intervention (on the same day as intervention)
|
|
Working memory measured with an n-back task - accuracy
Time Frame: Assessed immediately before and after the intervention (on the same day as intervention)
|
The change in accuracy on the n-back task
|
Assessed immediately before and after the intervention (on the same day as intervention)
|
|
Working memory measured with an n-back task - reaction time
Time Frame: Assessed immediately before and after the intervention (on the same day as intervention)
|
The change in measures of reaction time on the n-back task
|
Assessed immediately before and after the intervention (on the same day as intervention)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post-prandial insulin response during an oral glucose tolerance test
Time Frame: Assessed during the intervention
|
Insulin Area Under the Curve (AUC)
|
Assessed during the intervention
|
|
Post-prandial glucose response during an oral glucose tolerance test
Time Frame: Assessed during the intervention
|
Glucose Area Under the Curve (AUC)
|
Assessed during the intervention
|
|
Matsuda index
Time Frame: Assessed during the intervention
|
Insulin Sensitivity measured with Matsuda index
|
Assessed during the intervention
|
|
Stumvoll metabolic clearance rate (MCR)
Time Frame: Assessed during the intervention
|
Insulin Sensitivity expressed as Stumvoll metabolic clearance rate
|
Assessed during the intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Dominika M Pindus, PhD, University of Illinois at Urbana-Champaign
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20633
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.